RESEARCH TRIANGLE PARK, N.C. - Largemouth Communications, a full-service public relations firm, has been selected by Addrenex Pharmaceuticals to promote their development of a pipeline of products targeting conditions arising from an overactive adrenergic system, the body's control center for regulating stress and a host of other physiologic functions.

"We recognized that Largemouth offered a strategic approach and deep understanding of the pharmaceutical community," said Stephen Butts, vice president of commercial operations for Addrenex Pharmaceuticals.

Key components of the program will include announcements of company milestones such as the recent supplemental new drug application (sNDA) filing with the U.S. Food and Drug Administration (FDA) for Clonicel, the company's lead compound developed for the treatment of attention deficit hyperactivity disorder (ADHD). In addition, Largemouth will conduct proactive editorial outreach to promote the company's story and executive leadership.

"Addrenex has developed a promising drug portfolio with impressive speed and precision," said Brandon Bryce, president and CEO of Largemouth Communications. "We are confident that our communications expertise will help Addrenex meet their goal of sharing this success with the pharmaceutical and business communities."

About Addrenex Pharmaceuticals
Addrenex Pharmaceuticals is a focused, specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, N.C., on the edge of Research Triangle Park. The company's mission is to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraine and post-menopausal symptoms.

In addition to its partnered programs, Clonicel (hypertension and ADHD) and ADX-415 (hypertension and menopausal flushing), Addrenex has two proprietary products in clinical development, ADX-N05 for the treatment of narcolepsy and ADX-117 for procedural sedation. For more information, visit www.addrenex.com.

About Largemouth Communications, Inc.
Largemouth Communications, Inc. is a full-service public relations firm that was established in July 2005. With headquarters in Research Triangle Park, N.C. and a presence in Charlotte and Pittsburgh, the firm provides professional media and corporate relations services to local, regional and national clients in technology, business-to-business, health care and consumer industries. For more information about Largemouth Communications, please visit www.largemouthpr.com.